Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination

Cancer Immunology, Immunotherapy, 05/14/2012

This HGG–IMMUNO recursive partitioning analysis (RPA) classification is able to predict overall survival in a large group of adult patients with a relapsed malignant glioma, treated with re–operation and postoperative adjuvant DC vaccination in the HGG–IMMUNO–2003 cohort comparison trial. The model appears useful for prognostic patient counseling for patients participating in dendritic cell (DC) vaccination trials. A substantial number of long–term survivors after relapse are seen in class I to III, but not in class IV patients.

Print Article Summary Cat 2 CME Report